Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market
Beta Drugs Ltd 路 Others (Uncategorized) 路 22 Sept 2026, 2:30 pm
Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market Beta Drugs received regulatory approvals in Azerbaijan for its oncology portfolio across liquid injectables, lyophilised injectables, tablets, capsules, and oral suspensions. The company has filed 15 oncology dossiers, with an additional 15 products ready for filing next month. Positioned to be among the few oncology players in the country, Beta Drugs is targeting commercialisation and initial business generation during the current financial year, aligning with its broader strategy to expand its international oncology franchise across emerging global markets.
Original exchange filing (PDF)
More announcements from Beta Drugs Ltd
- BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Nov-2026 to consider Other business. 路 16 Nov 2026
- To consider other business matters 路 16 Nov 2026
- Monitoring Agency Report as on 30th September, 2026 路 12 Nov 2026
- Beta Drugs Limited has informed the Exchange about Transcript 路 28 Oct 2026
- Beta Drugs Limited has informed the Exchange about Link of Recording 路 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 路 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Presentation 路 22 Oct 2026
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 22 Oct 2026
